Search
AI News: Alameda based Infinimmune launched its GLIMPSE-1 antibody engineering platform that is based on a protein language model focused on native human antibody sequences
Co-Founder and CEO Wyatt McDonnell describes why Infinimmune believes that learning directly from the human adaptive immune system is an...
Jun 19
Draig Therapeutics launched from stealth today with a total of $140M investments to tackle neuropsych conditions. Co-Founder & Executive Chair Ruth McKernan tells the backstory and why she is excited
An Operating Partner at SV Health Investors, she describes how the company came together after reaching out to Cardiff University...
Jun 18
BIO International 2025: Sweden's Alligator has a phase three ready CD40 asset for pancreatic cancer and is looking for a partner to move it forward
CEO Søren Bregenholt describes Alligators phase 2 data, as well as regulatory feedback it has received regarding the phase three trial...
Jun 18
BIO International 2025: The new CEO of Sweden's Hansa Biopharma discusses potential uses of the company's IgG busting drug, imlifidase, including for kidney transplant and along with gene therapy
Renée Aguiar-Lucander describes the kidney transplant population that the therapy currently has conditional approval with the EMA for,...
Jun 18
Lisa Deschamps of AviadoBio and Richard Wilson of Astellas discuss the field of AAV gene therapy, and their partnership on AVB-101, an AAV gene therapy for frontotemporal dementia (FTD)
Lisa and Richard describe the unmet need for frontotemporal dementia and their partnership on AVB-101, which is administered directly to...
Jun 18
Cardiff-based Draig Therapeutics launched today in the neuro space with a total investment of $140 million, with lead program DT-101, an AMPA receptor PAM, ready for P2 in Major Depressive Disorder
Professor Simon Ward of Cardiff University’s Medicines Discovery Institute, and Scientific Co-founder and CSO Draig, describes the...
Jun 17
BIO International 2025: Oppenheimer's Head of Healthcare Investment Banking, Michael Margolis, discusses biotech sentiment, M&A, and what it is like to raise money today
He describes how sentiment and the M&A environment have been improving, as well as some areas of the financing market. However, he...
Jun 17
BIO International 2025: Perspective Therapeutics CEO Thijs Spoor describes why the company prefers radiopharmaceuticals with alpha-particles, and breaks down three main programs
He describes why he likes the strong and quick elements of alpha-particles, and how Perspective's have been designed to have a short...
Jun 17
BIO International 2025: CEO Paul Hastings discusses the progress Nkarta is making on its NK cell approach to autoimmune conditions
He describes why he believes NK cells are better suited thank T-cells for autoimmune, and updates us on the company's clinical programs....
Jun 17
BIO International 2025: Germany's Aicuris, a company that focuses on helping immunocompromised patients, has breakthrough therapy designation for its HSV treatment that is in a pivotal
CEO Larry Edwards describes the unmet need in the immunocompromised space, and highlights Aicuris' commercial CMV product (PREVYMIS),...
Jun 17
BIO International 2025: UroGen CEO Liz Barrett discusses last week's approval of ZUSDURI for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer
She describes the unmet need for a new therapy in this setting, and compares and contrasts ZUSDURI to going through multiple...
Jun 16
BIO International 2025: CEO Steve Favaloro introduces us to Genezen - a best-in-class CDMO with a preclinical to commercial offering
From the floor of the BIO International Convention, he describes the services that Genezen offers, its growth, and how it can partner...
Jun 16
BIO International 2025: eGenesis CEO Mike Curtis discusses the case of the second patient who has received a transplant using the company's genetically engineered porcine kidney, and what is next
He describes the successful transplant of Tim Andrews, who threw out the first pitch at a Red Socks game last week, and discusses what is...
Jun 16
BIO International 2025: Stifel's Tim Opler comments on improvements in sentiment he is seeing for the biotech sector, and his take on hot button issues
He explains how M&A and fundraising have been improving, and he describes what types of companies have been most appealing to investors....
Jun 16
BIO International 2025: An intro to the BIO International Convention, and stopping by the Korea Pavilion
From the floor of the 2025 BIO International Convention in Boston, Brad Loncar describes what this four-day conference is all about, and...
Jun 16
BIO International 2025: Ocugen CEO Shankar Musunuri discusses the company's gene therapy platform for eye conditions - one of which is already in a pivotal, with another to start
He discusses the company's gene therapy approach to retinitis pigmentosa, Stargardt disease (which just had a pivotal cleared by FDA...
Jun 16
Welcoming Genezen to the BiotechTV family today as a new sponsor
Genezen is a best-in-class CDMO with over a decade of experience and state-of-the-art viral vector facilities. Genezen's advanced...
Jun 16
BioVenture VoiCes Episode 21: Scion Life Sciences' Aaron Kantoff
Aaron Kantoff describes the road on the public markets side that eventually led him to venture, and recalls successful investments he...
Jun 16
EHA 2025: Arcellx CEO Rami Elghandour discusses the results presented today of the iMMagine-1 Study for the company's BCMA CAR-T
He goes over the results, and compares and contrasts the therapy's profile to the primary competitor that is currently on the market,...
Jun 14
EHA 2025: The CEO of Ascentage Pharma, which had its U.S. IPO earlier this year, introduces us to the company and discusses BCR-ABL, Bcl-2, and EED targeting programs
Dajun Yang shares the history of Ascentage, talks about what makes the BCR-ABL program, which Takeda took an option on, a...
Jun 14
.png){kind=logo}
